Indrayani Biotech Limited (INDRANIB) Fair Value & Analysis
Industrials · IN · Market cap ₹388M
Fair value as of: Jul 5, 2026
From 6 valuation models · updated today
Share price −25.7% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹6.90 – ₹15.94 · fair‑value band ₹7.96 – ₹15.92 · the ₹8.52 price screens below the ₹10.67 fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Indrayani Biotech Limited (INDRANIB) currently trades at ₹8.52, while our model-based Fair Value estimate is ₹10.67 — implying the stock looks roughly 25.2% undervalued today. We read business quality at 26/100 (below-average quality), in the Industrials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, Indrayani Biotech Limited generated revenue of ₹1.5B at a net margin of -1.9%. Revenue grew 102.2% year over year. It earns a return on equity of -6.9%. Net debt stands at ₹1.4B. Fundamentals as of Jul 5, 2026
Our scenario range runs from ₹7.96 (bear case) to ₹15.92 (bull case); at ₹8.52, the current price sits within that range. The share trades about 48% below its 52-week high and 40% above its 52-week low, currently below its 200-day average. For context, the median of 10 Industrials peers we cover trades at -29% fair-value upside — at 25%, INDRANIB screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
About the company
Indrayani Biotech Limited, together with its subsidiaries, engages in the engineering, food and hospitality, dairy, healthcare and pharma, engineering, infrastructure, agriculture, and biotech businesses. It operates food court chains under the Nalla Sappadu brand; offers catering services; and food supply services. It also designs, develops, manufactures, and maintains, and services power electronics. Its products include FCBC, battery chargers, modulars, industrial and commercial on-line UPS systems, industrial inverters, AC/DC power supplies, DC-DC converters, servo-controlled voltage stabilizers, automatic rescue devices, and special purpose machines. In addition, it markets and sells microorganisms based bio fertilizers, bio pest controllers, bio fortified vermi compost and bio fortified coirpoth, as well as pseudomonas, beauveria bassiana, metarhizium, potash mobiliser, tricoderma viride, verticillium lecanii, humic acid, bio fortified coirpith compost, bio fortified …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Indrayani Biotech Limited reported revenue of ₹1.3B in FY2025 versus ₹211M in FY2021, a compound +57.6%/yr. Reported net income was −₹61.1M in FY2025.
Is INDRANIB fairly valued? → Check now
Similar stocks
10 more Specialty Business Services stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Cintas Corporation CTAS | $180.40 | $74.70 | -59% |
| RELX PLC R1EL34 | R$45.28 | R$23.22 | -49% |
| Thomson Reuters Corporation TRI | C$120.12 | C$85.63 | -29% |
| Copart, Inc CPRT | $29.48 | $34.05 | +16% |
| Global Payments Inc GPN | $62.47 | $51.51 | -18% |
| UL Solutions Inc ULS | $97.38 | $29.61 | -70% |
| RB Global, Inc RBA | $104.49 | $46.94 | -55% |
| Brambles Limited BMBLF | $13.70 | $11.89 | -13% |
| Wolters Kluwer N.V WOSB | €61.14 | €57.13 | -7% |
| Rentokil Initial plc RTO | $28.50 | $19.63 | -31% |
Explore undervalued stocks
More undervalued Industrials stocks →
Frequently asked questions
Is Indrayani Biotech Limited (INDRANIB) undervalued?
What is the fair value of INDRANIB?
What is the quality score of INDRANIB?
What is the revenue of Indrayani Biotech Limited (INDRANIB)?
What is the net profit margin of INDRANIB?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.